Abstract
The pharmacokinetics of hydroxyurea (HU) were investigated in cancer patients after intravenous infusion or oral administration. On the basis of the minimal value of the objective function (MVOF) and prior knowledge of the disposition of HU in animals and man, the data were best described by a one-compartment pharmacokinetic model with parallel Michaelis-Menten metabolism and first-order renal excretion. The computer program NONMEM (nonlinear mixed effects model) was used to perform the nonlinear regression and provide estimates of the population parameters. For the combined intravenous and oral data set, these parameters were estimated to be: maximal elimination rate (V max), 0.097 mmolh−1 l−1; Michaelis constant for HU elimination (K M), 0.323 mmol/1; renal clearance (Cl R), 90.8 ml/min; volume of distribution (V d), 0.186× (body weight) + 25.41; absorption rate constant (K a), 2.92 h−1; and availability to the systemic circulation (F), 0.792. The principal findings of the investigation are that HU undergoes nonlinear elimination in cancer patients and that HU is reasonably well absorbed following oral administration.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Adamson RH, Ague SL, Hess SM, Davidson JD (1965) The distribution, excretion, and metabolism of hydroxyurea-14C. J Pharmacol Exp Ther 150: 322
Beal SL, Sheiner LB (1989) NONMEM users guide, part I. Users basic guide. Technical report. University of California Press, San Francisco
Beal SL, Boeckmann AJ, Sheiner LB (1989) NONMEM users guide, part VI. PREDPP guide. Technical report. University of California Press, San Francisco
Beckloff GL, Lerner HJ, Frost D, Russo-Alesi FM, Gitomer S (1965) Hydroxyurea (NSC-32065) in biological fluids: dose-concentration relationship. Cancer Chemother Rep 48: 57
Belt RJ, Haas CD, Kennedy J, Taylor S (1980) Studies of hydroxyurea administered by continuous infusion. Cancer 46: 455
Boeckmann AJ, Sheiner LB, Beal SL (1989) NONMEM users guide, part V. Introductory guide. Technical report. University of California Press, San Francisco
Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, Milner PFA, Orringer EP, Philips G, Platt, S, Thomas GH (1992) Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 79: 2555
Colvin M, Bono VH (1970) The enzymatic reduction of hydroxyurea to urea by mouse liver. Cancer Res 30: 1516
Dover GJ, Humphries RK, Moore JG, Ley TJ, Young NS, Charache S, Nienhuis AW (1986) Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production. Blood 67: 735
Elford HL (1968) Effect of hydroxyurea on ribonucleotide reductase. Biochem Biophys Res Commun 33: 129
Fabricius E, Rajewsky MF (1971) Determination of hydroxyurea in mammalian tissues and blood. Rev Eur Etudes Clin Biol 16: 679
Holmberg A (1982) On the problem of practical identifiability of microbial growth models incorporating Michaelis-Menten type nonlinearities. Math Biosci 62: 23
Navarra P, Del Carmine R, Ciabattoni G, D’Amato M, Ragazzoni E, Vacca M, Volpe AR, Preziosi P (1990) Hydroxyurea: relationship between toxicity and centrally-induced adrenal activation. Pharmacol Toxicol 67: 209
Nihtila N, Virkkunen J (1971) Practical identifiability of growth and substrate consumption models. Biotech Bioeng 19: 1831
Philips FS, Sternberg SS, Schwartz HS, Cronin AP, Sodergren JE, Vidal PM (1967) Hydroxyurea. I. Acute cell death in proliferating tissues in rats. Cancer Res 27: 61
Tong DDM, Metzler, C (1980) Mathematical properties of compartmental models with Michaelis-Menton type elimination. Math Biosci 48: 293
Tracewell WG, Vaughan WP, Gwilt PR (1992) Pharmacokinetics of hydroxyurea in the rat. Pharm Res 9: S260
Vaughan WP (1985) Clinical and laboratory studies of the synergistic combination of hydroxyurea (HU) with 4’-(9-acridinylamino)-methanesulfon-M-anisidide (AMSA) and cyclophosphamide (CY) for acute myelocytic leukemia (AML) (abstract 727). Blood 66: 210a
Vaughan WP, Holm C, Cordel K (1989) Hydroxyurea potentiation of the anti-neoplastic activity of cyclophosphamide and 4’-(9-acridinylamino)-methanesulfon-M-anisidide (AMSA) in the Brown Norway rat myelocytic leukemia. Cancer Chemother Pharmacol 23: 26
Vaughan WP, Reed EC, Kessinger A (1991) High-dose cyclophosphamide, thiotepa, hydroxyurea with autologous hematopoietic stem cell rescue: an effective regimen for consolidation chemotherapy of early metastatic breast cancer. In: Autologous bone marrow transplantation: proceedings of the 5th international symposium. The University of Nebraska Press, Omaha, p 343
Vaughan WP, Kris ES, Vose JM, Bierman PJ, Nelson JM, Frappier B, Gwilt PR, Kessinger A, Armitage JO (1991) Phase I/IV clinical trial of IV hydroxyurea (HU) in combination with BCNU (B), etoposide (E) and cytoxan (C) followed by autologous marrow or peripheral stem cell reinfusion (ABMT) for aggressive non-Hodgkin lymphoma (NHL) (abstract 948). Blood 78: 239a
Veale D, Cantwell BMJ, Kerr N, Upfold A, Harris AL (1988) Phase I study of hydroxyurea in lung cancer. Cancer Chemother Pharmacol 21: 53
Author information
Authors and Affiliations
Additional information
Supported in part by NIH NCI grant 5-R01-CA45529
Rights and permissions
About this article
Cite this article
Tracewell, W.G., Trump, D.L., Vaughan, W.P. et al. Population pharmacokinetics of hydroxyurea in cancer patients. Cancer Chemother. Pharmacol. 35, 417–422 (1995). https://doi.org/10.1007/s002800050256
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s002800050256